ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,00%
Dow Jones
38 884,26
0,08%
DAX
18 438,53
0,00%
Brent Oil
82,465
-0,48%
Bitcoin
62 387,33
0,08%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA Intellia Therapeutics Inc

23,90
0,18 (0,76%)
08 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Intellia Therapeutics Inc NTLA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,18 0,76% 23,90 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
23,77 23,29 24,09 23,88 23,72
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202413:30GLOBEIntellia Therapeutics to Hold Conference Call to Discuss..
29/4/202413:30GLOBEIntellia Therapeutics to Present Updated Data from Phase 1/2..
18/3/202412:30GLOBEIntellia Therapeutics Announces First Patient Dosed in the..
05/3/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202413:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/2/202423:17EDGAR2Form 8-K - Current report
22/2/202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202422:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:45EDGAR2Form 8-K - Current report
22/2/202413:30GLOBEIntellia Therapeutics Announces Fourth Quarter and Full-Year..
15/2/202413:30BWIntellia Therapeutics and ReCode Therapeutics Announce..
14/2/202413:30GLOBEIntellia Therapeutics to Hold Conference Call to Discuss..
01/2/202422:05EDGAR2Form 8-K - Current report
31/1/202423:00GLOBEIntellia Therapeutics Announces Publication of Positive..
29/1/202422:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:05EDGAR2Form 144 - Report of proposed sale of securities
05/1/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 8-K - Current report
04/1/202422:01GLOBEIntellia Therapeutics Highlights its Three-Year Strategic..
03/1/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202313:00EDGAR2Form 8-K - Current report
24/11/202315:30EDGAR2Form S-3ASR - Automatic shelf registration statement of..
14/11/202313:30GLOBEIntellia Therapeutics Receives European Union Orphan Drug..
09/11/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:45EDGAR2Form 8-K - Current report
09/11/202313:30GLOBEIntellia Therapeutics Announces Third Quarter 2023 Financial..
02/11/202321:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202312:11EDGAR2Form 8-K - Current report
02/11/202312:00GLOBEIntellia Presents New Interim Data from the Ongoing Phase 1..
26/10/202313:30GLOBEIntellia Therapeutics to Present Updated Data from Ongoing..
18/10/202313:30EDGAR2Form 8-K - Current report
18/10/202313:00GLOBEIntellia Therapeutics Announces FDA Clearance of..
13/10/202314:38GLOBEIntellia Therapeutics Receives Priority Medicines (PRIME)..
03/10/202313:19EDGAR2Form 8-K - Current report
03/10/202313:00GLOBERegeneron and Intellia Announce Expanded Research..
03/8/202322:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202313:45EDGAR2Form 8-K - Current report
03/8/202313:30GLOBEIntellia Therapeutics Announces Second Quarter 2023..
02/8/202323:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202322:45EDGAR2Form 144 - Report of proposed sale of securities

Dernières Valeurs Consultées

NASDAQ
NTLA
Intellia Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés